Welcome to our dedicated page for Tourmaline Bio news (Ticker: TRML), a resource for investors and traders seeking the latest updates and insights on Tourmaline Bio stock.
Tourmaline Bio Inc reports clinical, financial, and corporate developments for a late-stage biotechnology company focused on immune and inflammatory diseases. Its recurring updates center on pacibekitug, also referred to as TOUR006, including data from the Phase 2 TRANQUILITY trial in cardiovascular inflammation and program activity in thyroid eye disease.
Company news also covers quarterly financial results, business highlights, scientific meeting presentations, biomarker data involving high-sensitivity C-reactive protein and IL-6 pathway activity, advisory-board activity, material agreements, governance matters, shareholder voting topics, capital-structure disclosure, and risk factors tied to its clinical-development strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.